Sjögren's Syndrome (Adult)

1. Clinical Overview

Summary

Sjögren's Syndrome (SS) is a chronic systemic autoimmune disease characterised by lymphocytic infiltration of exocrine glands, predominantly affecting the lacrimal and salivary glands. This results in the hallmark sicca syndrome: keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth). [1,2]

SS can be classified as:

• Primary Sjögren's Syndrome (pSS): Occurring in isolation without another connective tissue disease
• Secondary Sjögren's Syndrome (sSS): Associated with another autoimmune condition, most commonly Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), or Systemic Sclerosis

The disease is mediated by autoantibodies (Anti-Ro/SSA and Anti-La/SSB), chronic B-cell hyperactivation, and formation of ectopic germinal centres within affected glands. Beyond glandular involvement, Sjögren's is a systemic disease with potential extraglandular manifestations affecting the musculoskeletal, pulmonary, renal, neurological, and haematological systems. [1,7]

The most significant long-term complication is a 44-fold increased risk of B-cell Non-Hodgkin Lymphoma, particularly mucosa-associated lymphoid tissue (MALT) lymphoma of the salivary glands. [6,9]

Key Clinical Features

Clinical Pearls

The Lymphoma Shadow: Sjögren's carries a 44-fold increased risk of B-cell Non-Hodgkin Lymphoma, particularly MALT lymphoma. Any persistent, hard, or unilateral parotid swelling warrants urgent investigation. Red flags for lymphoma transformation include: declining C4, new cryoglobulinaemia, rising RF, palpable purpura, lymphadenopathy, and splenomegaly. [6,9]

It's Not Just Dry Eyes and Mouth: Sjögren's is a systemic autoimmune disease. Extraglandular manifestations occur in 40-50% of patients and include: profound fatigue (nearly universal), arthralgia, interstitial lung disease (ILD), renal tubular acidosis (Type 1 - distal RTA), peripheral neuropathy, cutaneous vasculitis, and cytopenias. These systemic features significantly impact quality of life and prognosis. [1,10]

Anti-Ro in Pregnancy - Neonatal Lupus and Congenital Heart Block: Women with Anti-Ro/SSA antibodies (even if asymptomatic for Sjögren's) have a 1-2% risk of their baby developing congenital complete heart block (CHB) and/or neonatal lupus erythematosus (NLE). This risk rises to 15-20% if a previous child was affected. All Anti-Ro positive pregnant women require serial fetal echocardiography from 16-24 weeks gestation. [2,13]

Schirmer's Test - Bedside Diagnosis: A simple, reproducible bedside test for keratoconjunctivitis sicca. A 5mm-wide strip of sterile filter paper is placed in the lower conjunctival sac (usually at the junction of middle and lateral third) for 5 minutes without anaesthesia (Schirmer I). ≤5mm wetting indicates significant aqueous tear deficiency. Schirmer II (with nasal stimulation) tests reflex tear production. [11,14]

Focal Lymphocytic Sialadenitis - The Diagnostic Gold Standard: Labial (minor) salivary gland biopsy showing focal lymphocytic sialadenitis with a focus score ≥1 (≥1 focus of ≥50 mononuclear cells per 4mm² of glandular tissue) is the most specific test for Sjögren's. The lymphocytic infiltrate consists predominantly of CD4+ T cells and B cells forming ectopic germinal centres. This finding scores 3 points in the 2016 ACR/EULAR classification criteria. [11,14]

The 44x Lymphoma Risk - Vigilance Required: Patients with primary Sjögren's have a standardised incidence ratio (SIR) of approximately 44 for developing B-cell Non-Hodgkin Lymphoma compared to the general population. The absolute lifetime risk is 5-10%. MALT (marginal zone) lymphoma of the parotid gland is the most common subtype. High-risk features include: cryoglobulinaemia, low C4, palpable purpura, lymphadenopathy, splenomegaly, and salivary gland enlargement. Annual surveillance and low threshold for biopsy are essential. [6,9]

---

2. Epidemiology

Prevalence and Incidence

• Global Prevalence: 0.5-1% of the general population (varies by diagnostic criteria used) [7]
• Incidence: Approximately 4-6 per 100,000 person-years
• Primary vs Secondary: Primary Sjögren's accounts for ~50% of cases; Secondary Sjögren's occurs in association with other autoimmune diseases

Associations with Other Autoimmune Diseases

Secondary Sjögren's Syndrome occurs in association with:

Exam Detail: ### Epidemiological Risk Factors

Genetic Susceptibility:

• HLA Associations: Strong association with HLA-DRB103:01 (DR3), DQA105:01, DQB1*02:01 in European populations [7]
• Non-HLA Genes: STAT4, IRF5, BLK, TNFAIP3 (genetic variants affecting B-cell signalling and interferon pathways)
• Family History: 12-fold increased risk if first-degree relative affected

Environmental Triggers (Postulated):

• Viral Infections: Epstein-Barr Virus (EBV), Hepatitis C Virus (HCV), Human T-lymphotropic Virus-1 (HTLV-1), Cytomegalovirus (CMV)
• Bacterial Infections: Evidence for role of oral microbiome dysbiosis [5]
• Hormonal Factors: Female predominance suggests role of oestrogen and X-chromosome gene dosage

Protective Factors:

• Cigarette smoking paradoxically associated with lower risk of pSS (unlike most autoimmune diseases)
• Mechanism unclear; may relate to immunomodulatory effects on mucosa

---

3. Aetiology and Pathophysiology

Disease Mechanism

Sjögren's Syndrome results from a complex interplay of genetic susceptibility, environmental triggers, and immune dysregulation leading to chronic autoimmune exocrinopathy.

Step-by-Step Pathogenesis

1. Genetic Predisposition + Environmental Trigger

• Individuals with HLA-DR3/DQ2 haplotype and susceptibility genes (STAT4, IRF5, BLK) are at increased risk
• Viral infection (particularly EBV) or other environmental trigger initiates immune activation in genetically susceptible host [1,2]

2. Epithelial Cell Activation and Apoptosis

• Salivary and lacrimal gland ductal epithelial cells become activated and express:
  • HLA Class II molecules (aberrant expression)
  • Co-stimulatory molecules (CD80, CD86)
  • Adhesion molecules (ICAM-1, VCAM-1)
• Epithelial cells present autoantigens (Ro/SSA, La/SSB ribonucleoproteins) to T cells
• Increased epithelial cell apoptosis releases autoantigens, perpetuating immune response [1,4]

3. Lymphocytic Infiltration (Focal Lymphocytic Sialadenitis)

• CD4+ T cells (predominantly Th1 and Th17 subsets) infiltrate exocrine glands
• B cells are recruited and form organised lymphoid structures
• Formation of ectopic germinal centres (tertiary lymphoid organs) within glands
• Lymphocytic foci contain ≥50 mononuclear cells per 4mm² (focus score) [11,14]

4. Cytokine and Chemokine Storm

• Overproduction of pro-inflammatory cytokines:
  • "Type I Interferons (IFN-α, IFN-β): Upregulated interferon signature in pSS"
  • "B-cell Activating Factor (BAFF): Promotes B-cell survival and autoantibody production"
  • "IL-6, IL-17, TNF-α: Drive inflammation and tissue damage"
• Chemokines (CXCL12, CXCL13) recruit lymphocytes to glands [1,2]

5. Autoantibody Production

• Polyclonal B-cell activation produces autoantibodies:
  • "Anti-Ro/SSA: Targets Ro52 and Ro60 ribonucleoproteins (60-70% of pSS)"
  • "Anti-La/SSB: Targets La ribonucleoprotein (30-40% of pSS; more specific)"
  • "Rheumatoid Factor (RF): Present in 50% (polyclonal IgM RF)"
  • "Anti-muscarinic-3 receptor antibodies: May mediate glandular dysfunction"

6. Glandular Destruction and Dysfunction

• Progressive destruction of acinar cells (secretory units) by:
  • Cytotoxic T cells (CD8+)
  • Pro-inflammatory cytokines
  • Apoptosis
• Replacement of functional parenchyma with fibrous tissue and fatty infiltration
• Reduced secretion of tears (aqueous deficiency) and saliva → Sicca syndrome [4]

7. Extraglandular Manifestations

• Immune complex deposition and small-vessel vasculitis cause systemic features:
  • Cryoglobulinaemic vasculitis (purpura, peripheral neuropathy)
  • Interstitial nephritis and renal tubular acidosis (Type 1)
  • Interstitial lung disease (lymphocytic interstitial pneumonitis, NSIP)
  • Peripheral neuropathy (axonal or demyelinating) [3,10]

8. Lymphomagenesis (B-cell Lymphoma Development)

• Chronic B-cell stimulation, BAFF overexpression, and ectopic germinal centres predispose to:
  • Monoclonal B-cell expansion
  • Oncogenic mutations (BCL6, MYC, TP53)
  • Transformation to MALT (mucosa-associated lymphoid tissue) lymphoma or other B-cell Non-Hodgkin Lymphomas [6,9]

Exam Detail: ### Molecular Pathophysiology - High-Yield for Exams

Type I Interferon Signature:

• Primary Sjögren's shows upregulation of interferon-stimulated genes (ISGs)
• IFN-α and IFN-β activate plasmacytoid dendritic cells (pDCs)
• Interferon pathway drives epithelial activation, lymphocyte recruitment, and B-cell hyperactivity
• Potential therapeutic target (anti-IFN antibodies under investigation) [1]

BAFF (B-cell Activating Factor) Overexpression:

• BAFF (also called BLyS) is markedly elevated in serum and salivary glands
• Promotes B-cell survival, class switching, and plasma cell differentiation
• Prevents normal B-cell apoptosis → autoantibody production
• Anti-BAFF therapy (belimumab) under investigation for pSS [2]

Muscarinic Receptor Autoantibodies:

• Anti-M3 muscarinic receptor antibodies found in 70-90% of pSS patients
• M3 receptors mediate cholinergic stimulation of secretion in exocrine glands
• Antibodies may block M3 signalling → functional glandular hyposecretion
• Controversial whether antibodies are pathogenic or epiphenomenon [13]

Ectopic Germinal Centre Formation:

• Salivary glands develop organised lymphoid structures resembling lymph nodes
• Express CXCL13 (B-cell chemoattractant), follicular dendritic cells, and T follicular helper cells
• Site of ongoing B-cell maturation, class switching, and somatic hypermutation
• Predisposes to lymphoma development (clonal B-cell expansion) [1,9]

Ro/SSA and La/SSB Autoantigens:

• Ro/SSA: Complex of Ro52 (TRIM21) and Ro60 proteins bound to Y RNAs
• La/SSB: RNA-binding protein associated with RNA polymerase III transcripts
• Both are ribonucleoproteins involved in RNA processing
• Antibodies may form immune complexes → complement activation, tissue damage
• Anti-Ro crosses placenta → neonatal lupus and congenital heart block [2]

---

4. Clinical Presentation

Glandular (Sicca) Manifestations

The hallmark features of Sjögren's Syndrome are dry eyes and dry mouth, resulting from lymphocytic infiltration and destruction of the lacrimal and salivary glands.

Ocular Manifestations (Keratoconjunctivitis Sicca)

Complications:

• Filamentary keratitis (mucus filaments adherent to cornea)
• Corneal epithelial erosions
• Corneal ulceration (severe cases)
• Corneal perforation (rare, sight-threatening emergency)
• Increased risk of blepharitis and bacterial keratitis [4]

Oral Manifestations (Xerostomia)

Physical Examination Findings:

• Dry Oral Mucosa: Mucosa appears dry, sticky, cracked
• Loss of Salivary Pool: Absence of saliva pooling under tongue
• Tongue Blade Sign: Tongue blade sticks to buccal mucosa (normally slides easily)
• Lipstick Sign: Lipstick adheres to dry teeth (in women) [14]

Salivary Gland Enlargement

• Parotid Gland Swelling: Most common
  • "Episodic/Recurrent: Due to inflammation (sialadenitis); tender, bilateral"
  • "Persistent/Progressive: Suspect lymphoma (MALT); usually painless, firm, unilateral [6,9]"
• Submandibular Gland Enlargement: Less common than parotid
• Differential: Bacterial sialadenitis (acute, painful), sarcoidosis, IgG4-related disease, HIV-DILS

Other Exocrine Gland Involvement

• Dry Skin (xerosis): Reduced sweat/sebaceous gland function
• Dry Vagina: Vaginal dryness → dyspareunia
• Dry Nasal Mucosa: Epistaxis, crusting
• Dry Respiratory Tract: Dry cough, hoarseness

Extraglandular (Systemic) Manifestations

Extraglandular features occur in 40-50% of patients with primary Sjögren's and significantly impact quality of life and prognosis. [1,10]

Constitutional

• Fatigue: Near-universal (> 90%); profound, debilitating; often the most disabling symptom
• Fever: Low-grade, intermittent (during flares)

Musculoskeletal

• Arthralgia: Very common (50-70%); polyarticular, symmetric, non-deforming
• Arthritis: Non-erosive inflammatory arthritis (10-20%); small joints (hands, wrists); Jaccoud's-like arthropathy (rare)
• Myalgia: Muscle pain without weakness
• Myositis: Frank inflammatory myositis (rare; exclude overlap with polymyositis)

Pulmonary (10-20%)

• Interstitial Lung Disease (ILD): [10]
  • "NSIP (Non-Specific Interstitial Pneumonia): Most common pattern"
  • "LIP (Lymphocytic Interstitial Pneumonitis): Lymphocytic infiltration; can mimic pulmonary lymphoma"
  • "UIP (Usual Interstitial Pneumonia): Rare"
  • "Presentation: Progressive dyspnoea, dry cough, bibasal crackles"
  • "HRCT: Ground-glass opacities, reticular pattern, septal thickening"
• Small Airway Disease: Follicular bronchiolitis, bronchiectasis
• Pleural Effusion: Rare; exudative, lymphocytic
• Pulmonary Hypertension: Rare; assess with echocardiography if dyspnoea disproportionate

Renal (5-10%)

• Renal Tubular Acidosis (RTA) Type 1 (Distal RTA): [3]
  • Defective H+ secretion in distal tubule
  • Hypokalaemia, non-anion gap metabolic acidosis, alkaline urine (pH > 5.5)
  • "Complications: Nephrocalcinosis (calcium phosphate stones), bone disease (osteomalacia)"
  • "Check: U&Es, VBG, urine pH"
• Interstitial Nephritis: Lymphocytic infiltration; may cause CKD
• Glomerulonephritis: Rare (2-3%); membranoproliferative (MPGN) or membranous; associated with cryoglobulinaemia

Neurological (10-20%)

Peripheral Nervous System:

• Sensory Polyneuropathy: Most common; small fibre (burning, dysaesthesia) or large fibre (vibration/proprioception loss)
• Sensory Ataxic Neuropathy: Proprioceptive loss → ataxia (Sjögren's sensory neuronopathy)
• Mononeuritis Multiplex: Asymmetric neuropathy; due to vasculitis
• Cranial Neuropathy: Trigeminal neuropathy (facial pain, sensory loss); others rare

Central Nervous System (Rare, 2-3%):

• Transverse myelitis, optic neuritis (NMO-spectrum disorder), aseptic meningitis, encephalitis
• CNS involvement is uncommon in Sjögren's; always exclude SLE, MS, or other causes

Dermatological

• Cutaneous Vasculitis: Small-vessel leucocytoclastic vasculitis
  • Palpable purpura (lower limbs)
  • Urticarial vasculitis
  • Associated with cryoglobulinaemia, low C4 [9]
• Annular Erythema: Erythema annulare centrifugum-like lesions
• Raynaud's Phenomenon: 30-40% of patients

Haematological

• Cytopenias: Leucopenia (lymphopenia), anaemia (chronic disease or haemolytic), thrombocytopenia
• Hypergammaglobulinaemia: Polyclonal IgG elevation (80%)
• Cryoglobulinaemia: Mixed cryoglobulinaemia (Type II or III); associated with vasculitis, lymphoma risk [9]
• Lymphopenia: CD4+ lymphopenia common

Gastrointestinal

• Dysphagia: Due to xerostomia or oesophageal dysmotility
• Gastritis/Atrophic Gastritis: Helicobacter pylori association (possible MALT lymphoma cofactor)
• Pancreatitis: Autoimmune pancreatitis (rare; overlap with IgG4-related disease)
• Primary Biliary Cholangitis (PBC): Strong association; 50-70% of PBC patients have sSS

Clinical Pearl: ### Sjögren's "Red Flag" Symptoms

Certain features suggest severe systemic disease or lymphoma transformation and require urgent investigation:

---

5. Differential Diagnosis

The sicca syndrome (dry eyes and dry mouth) is not specific to Sjögren's. A broad differential must be considered.

Primary Differential: Causes of Dry Eyes and Dry Mouth

Parotid Swelling Differential

---

6. Investigations

Diagnostic Approach

The diagnosis of Sjögren's Syndrome requires a combination of:

1. Clinical features (sicca symptoms)
2. Objective evidence of ocular/oral dryness (Schirmer test, ocular staining, salivary flow)
3. Serological markers (Anti-Ro/SSA, Anti-La/SSB)
4. Histopathology (focal lymphocytic sialadenitis on labial gland biopsy)

The 2016 ACR/EULAR Classification Criteria are the current gold standard for classification (research) and widely used for diagnosis. [11]

2016 ACR/EULAR Classification Criteria for Primary Sjögren's Syndrome

Inclusion Criteria:

• At least one of the following symptoms:
  • Daily, persistent, troublesome dry eyes for > 3 months
  • Recurrent sensation of sand/gravel in the eyes
  • Use of tear substitutes > 3 times/day
  • Daily feeling of dry mouth for > 3 months
  • Frequently drink liquids to swallow dry food

Exclusion Criteria:

• History of head/neck radiation
• Active Hepatitis C infection (HCV PCR positive)
• AIDS
• Sarcoidosis
• Amyloidosis
• Graft-versus-host disease
• IgG4-related disease

Scoring System (Score ≥4 = Primary Sjögren's Syndrome):

Interpretation:

• Score ≥4: Definite Primary Sjögren's Syndrome
• Most patients score either 5 (Anti-Ro + lip biopsy + one ocular/oral test) or 6 (all positive)
• Patients negative for Anti-Ro typically require lip biopsy + multiple objective tests [11,14]

Serology

Exam Detail: Anti-Ro (SSA) and Anti-La (SSB) Technical Details:

• Anti-Ro/SSA: Targets two proteins:

  • "Ro52 (TRIM21): 52 kDa protein; E3 ubiquitin ligase"
  • "Ro60: 60 kDa protein; binds Y RNAs (small non-coding RNAs)"
  • Both form ribonucleoprotein complexes

• Anti-La/SSB: Targets La protein (47 kDa); RNA polymerase III termination factor

• Clinical Implications of Anti-Ro:

  • Associated with earlier disease onset
  • Higher risk of systemic features (arthritis, vasculitis, ILD)
  • Predicts lymphoma risk
  • Crosses placenta → neonatal lupus, congenital heart block (1-2% risk) [2]

• Anti-La alone without Anti-Ro: Very rare (less than 2% of Sjögren's); question diagnosis

Ocular Assessment

Schirmer's Test

Schirmer I (Without Anaesthesia):

• Measures basal + reflex tear secretion
• Procedure: 5mm-wide sterile filter paper strip (Whatman No. 41) placed in lower conjunctival sac at junction of lateral and middle third; eyes closed gently for 5 minutes
• Normal: > 10 mm wetting
• Abnormal: ≤5 mm wetting (diagnostic for aqueous deficiency)
• Borderline: 6-10 mm (repeat or use other tests) [14]

Schirmer II (With Anaesthesia + Nasal Stimulation):

• Tests reflex tear secretion
• Topical anaesthetic applied; nasal mucosa stimulated
• Less commonly used clinically

Ocular Surface Staining

• Rose Bengal or Lissamine Green Staining: Stains dead/devitalised epithelial cells
• Fluorescein Staining: Stains corneal epithelial defects
• Ocular Staining Score (OSS): Assesses cornea and conjunctiva; score ≥5 diagnostic (or van Bijsterveld score ≥4)
• Requires slit-lamp examination (ophthalmology referral) [11,14]

Tear Break-Up Time (TBUT)

• Time for dry spot to appear on cornea after blink
• Normal: > 10 seconds
• Abnormal: less than 5 seconds (tear film instability)

Oral Assessment

Unstimulated Whole Salivary Flow

• Patient spits into container for 15 minutes
• Normal: > 0.1 mL/min (> 1.5 mL total)
• Abnormal: ≤0.1 mL/min (severe hyposecretion)
• Scores 1 point in ACR/EULAR criteria [11]

Stimulated Salivary Flow

• Salivary flow measured with gustatory stimulation (citric acid, paraffin wax chewing)
• Less commonly used for diagnosis

Labial Salivary Gland Biopsy (Minor Gland Biopsy)

Gold Standard for Diagnosis:

Procedure:

• Minor salivary glands harvested from lower lip mucosa (usually 4-6 glands)
• Local anaesthetic; small incision on inner lip
• Minimal morbidity (temporary numbness, rare scarring)

Histopathology:

• Focal Lymphocytic Sialadenitis: Lymphocytic infiltrate forming discrete foci
• Focus: Aggregate of ≥50 mononuclear cells (lymphocytes, plasma cells) adjacent to normal-appearing acini
• Focus Score: Number of foci per 4 mm² of glandular tissue
  • "Focus Score ≥1: Diagnostic (scores 3 points in ACR/EULAR criteria)"
  • Predominantly CD4+ T cells and B cells
• Ectopic Germinal Centres: Organised lymphoid structures (seen in 20-30%; associated with higher lymphoma risk) [11,14]

Exclusions on Biopsy:

• Sarcoidosis: Non-caseating granulomas
• IgG4-RD: Storiform fibrosis, IgG4+ plasma cells
• Lymphoma: Monoclonal lymphoid infiltrate

Salivary Gland Imaging

Ultrasound (US)

• Findings in Sjögren's: Heterogeneous parenchyma, hypoechoic areas, loss of normal gland architecture
• OMERACT US Scoring: Grades 0-4 based on echotexture heterogeneity
• Non-invasive, increasingly used for diagnosis and monitoring [14]

MRI Salivary Glands

• Findings: Heterogeneous signal, cystic changes, fatty infiltration
• High sensitivity; expensive; not routinely required

Sialography

• Contrast injection into salivary ducts
• Findings: Contrast extravasation (sialectasis), ductal dilatation
• Now largely replaced by ultrasound/MRI (invasive, risk of contrast reaction)

Systemic Screening and Monitoring

Baseline Investigations (All Patients)

• FBC: Cytopenias (lymphopenia, anaemia, thrombocytopenia)
• U&Es: Hypokalaemia (RTA), renal function
• LFTs: Associated autoimmune hepatitis, PBC (raised ALP, GGT)
• Bone Profile: Hypercalcaemia (sarcoidosis differential); low K, high Ca in RTA
• ESR/CRP: Usually normal or mildly elevated (not a marker of activity)
• Urinalysis: Proteinuria (GN), pH > 5.5 despite acidosis (RTA)
• Serum Protein Electrophoresis (SPEP): Polyclonal gammopathy (80%); monoclonal spike (lymphoma) [9]
• Complement C3/C4: Low C4 is lymphoma risk factor [9]
• Cryoglobulins: If vasculitis, purpura, or low C4 [9]
• Thyroid Function (TFT): Screen for autoimmune thyroid disease (10-15% overlap)
• Hepatitis B/C Serology: HCV can mimic Sjögren's; HBV before immunosuppression

Annual Surveillance (Monitor for Lymphoma and Complications)

• Clinical Examination: Parotid/lymph nodes, spleen, purpura
• FBC, U&Es, LFTs, SPEP: New cytopenias, monoclonal spike
• Complement C4: Declining C4 suggests lymphoma risk [9]
• Cryoglobulins: New cryoglobulinaemia is red flag
• RF: Rising RF may indicate lymphoma transformation
• CXR or HRCT (if respiratory symptoms): ILD surveillance [10]

Investigations for Suspected Extraglandular Disease

---

7. Management

Management of Sjögren's Syndrome is multimodal, combining:

1. Symptomatic treatment for sicca symptoms (tears, saliva, pilocarpine)
2. Systemic immunosuppression for extraglandular manifestations
3. Lymphoma surveillance
4. Multidisciplinary care (rheumatology, ophthalmology, dentistry)

The 2020 EULAR recommendations provide evidence-based guidance. [16]

Management Algorithm

            SJÖGREN'S SYNDROME DIAGNOSED
       (ACR/EULAR Criteria ≥4 or Clinical Diagnosis)
                     ↓
              ASSESS SEVERITY
       ┌──────────────┴─────────────────┐
   SICCA ONLY                   EXTRAGLANDULAR
   (Mild disease)                 (Systemic disease)
        ↓                               ↓
   SYMPTOMATIC                   SYSTEMIC TREATMENT
   MANAGEMENT                           ↓
        ↓                    ┌──────────┴──────────┐
   - Artificial tears       MILD/MODERATE      SEVERE/ORGAN-
   - Saliva substitutes     (Arthralgia,       THREATENING
   - Pilocarpine            fatigue)           (ILD, vasculitis,
   - Ciclosporin drops           ↓             neuropathy)
   - Punctal plugs          - Hydroxychloroquine    ↓
   - Dental care                 ↓             - Corticosteroids
                            If inadequate:      - Rituximab
                            - Methotrexate      - Cyclophosphamide
                            - Azathioprine      - IVIG (neuropathy)
                                 ↓
                      LYMPHOMA SURVEILLANCE
                      - Annual examination
                      - Monitor C4, RF, SPEP
                      - Low threshold for biopsy

1. Sicca Symptom Management

Dry Eyes (Keratoconjunctivitis Sicca)

Ophthalmology Referral Indications:

• Moderate-severe dry eye (Schirmer ≤2 mm, corneal staining)
• Vision-threatening complications (corneal ulceration)
• Poor response to topical therapy

Dry Mouth (Xerostomia)

Pilocarpine:

• Mechanism: Muscarinic M3 receptor agonist → stimulates exocrine secretion
• Dose: 5 mg three to four times daily (start low, titrate up)
• Side Effects: Sweating (most common, 30-40%), flushing, nausea, urinary frequency, bradycardia
• Contraindications: Asthma (bronchospasm), narrow-angle glaucoma, severe cardiac disease
• Evidence: Modest improvement in xerostomia (NNT ~6) [16,17]

Dental Care (Critical in Sjögren's)

• High-Fluoride Toothpaste (prescription strength 2800-5000 ppm)
• Fluoride Gel/Mouthwash: Daily application
• Chlorhexidine Mouthwash: Reduce bacterial load; avoid alcohol-containing mouthwashes
• Regular Dental Review: Every 3-6 months (high caries risk)
• Sugar-Free Diet: Avoid sugary foods/drinks
• Treat Oral Candidiasis: Nystatin or fluconazole if thrush

2. Systemic Treatment (Extraglandular Manifestations)

Mild-Moderate Systemic Disease (Fatigue, Arthralgia)

Hydroxychloroquine (First-line systemic therapy):

• Dose: 200-400 mg daily (≤5 mg/kg/day based on ideal body weight)
• Indications: Fatigue, arthralgia, mild skin involvement
• Evidence: Improves fatigue and arthralgia; reduces RF and hypergammaglobulinaemia [16,17]
• Monitoring: Baseline eye exam; annual screening for retinopathy (> 5 years use)
• Side Effects: Retinopathy (rare, cumulative dose-dependent), GI upset, rash

NSAIDs:

• For arthralgia; use lowest effective dose
• Risk of GI/renal side effects

Low-Dose Corticosteroids (Avoid long-term use):

• Prednisolone ≤10 mg daily for short-term symptom control during flares
• Long-term steroids ineffective for sicca and increase side effects [16]

Moderate Systemic Disease (Arthritis, Cutaneous Vasculitis)

Methotrexate:

• Dose: 10-25 mg weekly (oral or subcutaneous)
• Indications: Persistent arthritis, cutaneous vasculitis unresponsive to hydroxychloroquine
• Evidence: Limited RCT evidence specific to Sjögren's; extrapolated from RA
• Monitoring: FBC, LFTs, U&Es every 3 months

Azathioprine:

• Dose: 1-2.5 mg/kg/day
• Alternative to methotrexate for arthritis or cytopenias
• Monitoring: FBC, LFTs; check TPMT before starting

Mycophenolate Mofetil (MMF):

• Alternative immunosuppressant; limited evidence

Severe/Organ-Threatening Disease (ILD, Vasculitis, Neuropathy, Cytopenias)

Corticosteroids (High-dose):

• Dose: Prednisolone 0.5-1 mg/kg/day (or IV methylprednisolone 500-1000 mg for 3 days in critical situations)
• Indications: Severe vasculitis, ILD, severe cytopenias, CNS involvement
• Duration: Taper over weeks-months; use steroid-sparing agents

Rituximab (Anti-CD20 monoclonal antibody):

• Dose: 1000 mg IV at Day 0 and Day 14 (RA protocol) or 375 mg/m² weekly x 4 (lymphoma protocol)
• Indications: [16,19]
  • Severe systemic disease (vasculitis, ILD, neuropathy)
  • Cryoglobulinaemic vasculitis
  • Severe cytopenias
  • Refractory disease
• Evidence: Mixed RCT results for primary endpoints (fatigue), but benefits in severe extraglandular disease [16,19]
• Monitoring: Infections (reactivation of HBV, PJP prophylaxis if needed), infusion reactions
• Side Effects: Infusion reactions, infections, hypogammaglobulinaemia

Cyclophosphamide:

• Reserved for life/organ-threatening disease (severe vasculitis, severe ILD, CNS involvement)
• Dose: IV pulse 500-750 mg/m² monthly x 6 months, or oral 1-2 mg/kg/day
• Side Effects: Haemorrhagic cystitis, infections, infertility, malignancy risk

IVIG (Intravenous Immunoglobulin):

• For severe neuropathy (especially sensory neuronopathy or mononeuritis multiplex)
• Dose: 2 g/kg over 2-5 days; repeat monthly

Interstitial Lung Disease (ILD) Management

• Mild, Stable ILD: Observation; serial PFTs and HRCT
• Progressive ILD: [10]
  • Corticosteroids (prednisolone 0.5-1 mg/kg, taper)
  • Rituximab (increasing evidence for efficacy)
  • Cyclophosphamide (severe, progressive)
  • Mycophenolate (steroid-sparing)
• Pulmonology MDT input essential

Renal Tubular Acidosis (Type 1) Management

• Alkali Replacement: [3]
  • Sodium bicarbonate 1-2 mmol/kg/day in divided doses
  • "Target: Normal serum bicarbonate (22-28 mmol/L)"
• Potassium Supplementation: Oral potassium chloride (hypokalaemia common)
• Monitor: U&Es, VBG, urine pH
• Treat Complications: Nephrocalcinosis, bone disease (vitamin D, calcium)

3. Lymphoma Surveillance and Management

Annual Clinical Surveillance: [6,9]

• Examine parotid glands, lymph nodes, spleen
• Ask about B symptoms (fever, night sweats, weight loss)
• Monitor for palpable purpura, new cytopenias

Annual Laboratory Surveillance:

• FBC (cytopenias)
• SPEP (monoclonal spike)
• Complement C4 (declining C4 is red flag)
• Cryoglobulins (new positivity)
• RF (rising titres)

High-Risk Features for Lymphoma: [6,9]

• Persistent/progressive parotid swelling (especially unilateral, hard)
• Lymphadenopathy
• Splenomegaly
• Palpable purpura
• Low C4
• Cryoglobulinaemia
• Monoclonal gammopathy

Investigation of Suspected Lymphoma:

• Biopsy (parotid, lymph node, bone marrow)
• CT or PET-CT staging
• Flow Cytometry (B-cell monoclonality)

Lymphoma Treatment:

• Managed by haematology-oncology
• MALT lymphoma: Rituximab ± chemotherapy; excellent prognosis if localised
• Other B-cell NHL: Standard chemotherapy protocols

4. Multidisciplinary Care

5. Pregnancy Management

Anti-Ro/SSA Positive Women:

• Risk: 1-2% risk of congenital complete heart block (CHB) in offspring [2,13]
• Higher Risk: 15-20% recurrence if previous affected child
• Surveillance:
  • Serial fetal echocardiography from 16-24 weeks gestation (weekly during high-risk period)
  • Monitor for AV block, bradycardia, pericardial effusion, endocardial fibroelastosis
• Prophylaxis (Controversial):
  • Hydroxychloroquine 400 mg daily throughout pregnancy (may reduce CHB risk; continue if already on HCQ)
  • Fluorinated steroids (dexamethasone) if incomplete heart block detected (limited evidence)
• Neonatal Lupus: Rash, cytopenias, hepatitis (self-limiting, resolves as maternal antibodies clear by 6 months)
• Pregnancy Outcomes: Generally good; slightly increased preterm delivery and low birth weight

---

8. Complications

Glandular Complications

B-cell Non-Hodgkin Lymphoma

Epidemiology:

• Lifetime Risk: 5-10% (44-fold increased risk vs general population) [6,9]
• Standardised Incidence Ratio (SIR): ~44 for all NHL; ~1000 for parotid MALT lymphoma

Types of Lymphoma:

• MALT (Mucosa-Associated Lymphoid Tissue) Lymphoma: Most common; marginal zone B-cell lymphoma; arises in parotid/salivary glands
• Diffuse Large B-cell Lymphoma (DLBCL): Aggressive; transformation from MALT or de novo
• Other: Follicular lymphoma, nodal marginal zone lymphoma

Pathogenesis:

• Chronic B-cell stimulation, BAFF overexpression, ectopic germinal centres → clonal B-cell expansion → oncogenic mutations [6,9]

Risk Factors for Lymphoma Transformation: [6,9]

• Low C4 (OR ~6)
• Cryoglobulinaemia (OR ~10)
• Palpable purpura (OR ~5)
• Lymphadenopathy
• Splenomegaly
• Anti-La antibody (paradoxically protective; anti-Ro alone higher risk)

Presentation:

• Persistent, progressive, or unilateral parotid swelling (hard, painless)
• Lymphadenopathy
• Splenomegaly
• B symptoms (fever, night sweats, weight loss)
• Cytopenias
• Monoclonal gammopathy on SPEP

Prognosis:

• MALT lymphoma: Excellent prognosis if localised (Stage I-II); 5-year survival > 90%
• DLBCL: More aggressive; standard chemotherapy (R-CHOP)

Extraglandular Complications

Cardiovascular and Thrombotic Risk

• Premature Atherosclerosis: Increased cardiovascular risk (mechanism: chronic inflammation)
• Pulmonary Hypertension: Rare but recognised
• No Increased Thrombotic Risk: Unlike SLE, antiphospholipid antibodies uncommon

Pregnancy Complications (Anti-Ro Positive)

• Congenital Complete Heart Block (CHB): 1-2% risk; permanent pacemaker required [2,13]
• Neonatal Lupus: Rash, cytopenias, hepatitis (transient)
• Preterm Delivery: Slightly increased risk

---

9. Prognosis and Outcomes

Overall Prognosis

• Glandular Disease: Generally good long-term prognosis with symptomatic management; sicca symptoms are chronic but manageable
• Systemic Disease: Prognosis depends on severity and pattern of organ involvement; extraglandular features worsen QOL
• Lymphoma: 5-10% lifetime risk; MALT lymphoma has excellent prognosis if localised; DLBCL more aggressive [6,9]

Mortality

• Standardised Mortality Ratio (SMR): Slightly increased (~1.5-2.0) compared to general population [7]
• Causes of Death:
  • Lymphoma (most significant cause of excess mortality)
  • Infections (immunosuppressive therapy)
  • Severe systemic vasculitis
  • Pulmonary complications (ILD, infection)
  • Cardiovascular disease

Quality of Life

• Sicca Symptoms: Chronic, debilitating; impact on daily activities (reading, eating, speaking)
• Fatigue: Profound, disabling in > 90%; poorly responsive to treatment; major driver of poor QOL
• Pain: Arthralgia, neuropathic pain
• Psychological Impact: Anxiety, depression (chronic disease, fatigue, appearance concerns)

Prognostic Factors

Disease Course

• Chronic, Relapsing-Remitting: Sicca symptoms are constant; systemic features may wax and wane
• Slow Progression: Glandular destruction progressive over years-decades
• Lymphoma Transformation: Can occur at any time; median time to lymphoma ~7-10 years after diagnosis

---

10. Prevention and Screening

Primary Prevention

• No established primary prevention (genetic/environmental triggers unclear)
• Avoid known triggers: Maintain good oral/ocular hygiene

Secondary Prevention (Early Detection and Complications)

Annual Screening:

• Clinical examination (parotid, lymph nodes, spleen)
• FBC, U&Es, LFTs, SPEP
• Complement C4, cryoglobulins (if previously positive or high risk)
• HRCT chest if respiratory symptoms (ILD surveillance) [10]

Lymphoma Surveillance: [6,9]

• High index of suspicion for persistent parotid swelling
• Monitor C4, RF, SPEP, cryoglobulins
• Low threshold for biopsy

Pregnancy Screening (Anti-Ro Positive):

• Serial fetal echocardiography 16-24 weeks [2,13]

Dental Surveillance:

• 3-6 monthly dental review
• High-fluoride toothpaste, fluoride gel

Ophthalmology Surveillance:

• Annual review if moderate-severe dry eye
• Monitor for corneal complications

Tertiary Prevention (Preventing Progression)

• Immunosuppression for active systemic disease (prevent organ damage)
• Smoking Cessation (although paradoxically protective for Sjögren's onset, smoking worsens ILD and CV risk)
• Cardiovascular Risk Reduction: Manage CV risk factors (hypertension, hyperlipidaemia)

---

11. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. TEARS Trial (Rituximab in Primary Sjögren's)

• Study: Randomised, double-blind, placebo-controlled trial (n=120)
• Intervention: Rituximab 1000 mg IV Day 0 and Day 14 vs placebo
• Primary Endpoint: Change in fatigue VAS at 24 weeks
• Results: Did not meet primary endpoint (no significant difference in fatigue). Some benefit in secondary outcomes (ocular staining, RF reduction)
• Conclusion: Rituximab not recommended for routine fatigue/sicca symptoms; reserved for severe systemic disease [19]
• Reference: Bowman SJ, et al. Lancet. 2017.

2. 2016 ACR/EULAR Classification Criteria Development and Validation

• Study: International multicentre study (n=4057)
• Objective: Develop and validate new classification criteria for pSS
• Results: 5-item weighted score; sensitivity 96%, specificity 95% vs expert diagnosis [11]
• Impact: Now standard for clinical diagnosis and research inclusion
• Reference: Shiboski CH, et al. Arthritis Rheumatol. 2017. PMID: 27785888

3. Sjögren's Syndrome and Lymphoma Risk (Meta-analysis)

• Study: Meta-analysis of 11 cohort studies
• Results: Standardised incidence ratio (SIR) for NHL = 13.8 (95% CI 8.5-21.5); parotid MALT lymphoma SIR ~1000 [6,9]
• Risk Factors: Cryoglobulinaemia, low C4, palpable purpura, lymphadenopathy
• Conclusion: Vigilance and surveillance essential
• Reference: Baldini C, et al. Nat Rev Rheumatol. 2024. PMID: 38982205

4. EULAR Recommendations for Sjögren's Management (2020)

• Study: Systematic literature review + expert consensus
• Recommendations: [16]
  • "Topical: Artificial tears, punctal plugs, ciclosporin drops"
  • "Systemic: Hydroxychloroquine for fatigue/arthralgia; rituximab for severe disease"
  • Pilocarpine for xerostomia (modest benefit)
  • Avoid long-term corticosteroids
• Reference: Ramos-Casals M, et al. Ann Rheum Dis. 2020. PMID: 31672775

5. Sjögren's Syndrome and Interstitial Lung Disease

• Study: Systematic review of pulmonary manifestations
• Prevalence: ILD in 10-20% of pSS patients (subclinical abnormalities in up to 50%)
• Patterns: NSIP most common, then LIP
• Management: Immunosuppression (corticosteroids, rituximab, cyclophosphamide) for progressive disease [10]
• Reference: Flament T, et al. Eur Respir Rev. 2016. PMID: 27246587

---

12. Patient and Layperson Explanation

What is Sjögren's Syndrome?

Sjögren's Syndrome (pronounced "SHOW-grens") is a long-term autoimmune condition where your immune system mistakenly attacks the glands that produce moisture in your body, particularly the tear glands (making tears) and salivary glands (making saliva). This causes very dry eyes and a very dry mouth, which are the main symptoms.

Why does it happen?

Your immune system, which normally fights infections, becomes confused and attacks your own body. We don't know exactly why this happens, but it's a combination of your genes and possibly a trigger like a viral infection. It is not contagious and not your fault.

What are the main symptoms?

• Dry Eyes: Your eyes feel gritty, like there's sand in them. They may burn, sting, or become red. You may find it difficult to read or use a computer for long periods.
• Dry Mouth: Your mouth feels very dry, making it hard to swallow dry food or speak for long. You may need to sip water constantly.
• Swollen Glands: The glands near your ears or under your jaw (parotid and submandibular glands) may swell up.
• Tiredness: Many people feel extremely tired (fatigue), which can be the most difficult symptom.
• Joint Pain: Your joints may ache, similar to arthritis.

Is it serious?

For most people, Sjögren's affects mainly the eyes and mouth, which is uncomfortable but manageable with treatment. However, it can also affect other parts of the body (lungs, kidneys, nerves), and there is a small increased risk of developing a type of cancer called lymphoma (affecting the immune system). This is why regular check-ups are important.

How is it diagnosed?

Your doctor will:

• Ask about your symptoms (dry eyes, dry mouth)
• Do blood tests to look for specific antibodies (Anti-Ro, Anti-La)
• Test your tear production (Schirmer test – a small piece of paper in your eye)
• Sometimes take a tiny biopsy of the saliva glands inside your lip (under local anaesthetic) to confirm the diagnosis

How is it treated?

There is no cure for Sjögren's, but treatments help manage symptoms:

For Dry Eyes:

• Artificial tears (eye drops) used frequently throughout the day
• Eye ointment at night
• Special anti-inflammatory eye drops (ciclosporin) if needed
• Tiny plugs in your tear ducts to keep tears in your eyes longer

For Dry Mouth:

• Saliva sprays or gels
• Chewing sugar-free gum to stimulate saliva
• Pilocarpine tablets (a medication that helps your glands produce more saliva)
• Sipping water frequently

For Tiredness and Joint Pain:

• Hydroxychloroquine (a tablet that helps reduce inflammation and tiredness)
• Painkillers for joint pain

Dental Care is Very Important:

• Your dry mouth increases the risk of tooth decay (cavities)
• Use high-fluoride toothpaste and see your dentist every 3-6 months

What should I watch out for?

Tell your doctor urgently if you notice:

• Persistent swelling of the glands in front of your ears or under your jaw (especially if hard or painless)
• Purple spots on your skin (purpura)
• Severe tiredness or weight loss
• Shortness of breath or persistent cough
• Numbness or tingling in your hands or feet

These could be signs of complications that need investigation.

What about pregnancy?

If you have Sjögren's and are pregnant (or planning pregnancy), tell your doctor. If you have a specific antibody called Anti-Ro, there is a small risk (1-2%) it can affect your baby's heart. You will have extra scans during pregnancy to monitor your baby's heart.

Can I live a normal life?

Yes! Most people with Sjögren's live full, active lives. The dry eyes and mouth are manageable with treatment, and regular monitoring helps catch any complications early. Fatigue can be challenging, but pacing yourself and using energy-saving strategies helps.

Where can I get more information and support?

• British Sjögren's Syndrome Association (BSSA): www.bssa.uk.net
• Sjögren's Syndrome Foundation (USA): www.sjogrens.org
• Versus Arthritis (UK): www.versusarthritis.org

---

13. Examination Focus

High-Yield Examination Questions

1. Autoantibodies in Sjögren's Syndrome

Question: A 52-year-old woman presents with dry eyes and dry mouth. Her ANA is positive (titre 1:640, speckled pattern). Which autoantibody is the most specific for primary Sjögren's Syndrome?

A. Anti-Ro (SSA) B. Anti-La (SSB) C. Anti-centromere D. Rheumatoid Factor E. Anti-dsDNA

Answer: B. Anti-La (SSB)

Explanation:

• Anti-La (SSB) is the most specific antibody for Sjögren's Syndrome (~98% specificity), though it is present in only 30-40% of patients (moderate sensitivity)
• Anti-Ro (SSA) is more sensitive (60-70%) but less specific (can be positive in SLE, subacute cutaneous lupus, neonatal lupus)
• Anti-La is almost never positive in isolation; it is usually accompanied by Anti-Ro
• Rheumatoid Factor is present in ~50% but is non-specific
• Anti-centromere is associated with limited systemic sclerosis (CREST syndrome)
• Anti-dsDNA is specific for SLE

2. Major Long-Term Complication

Question: A 45-year-old woman with a 10-year history of primary Sjögren's Syndrome attends for annual review. She has been stable on symptomatic treatment (artificial tears, pilocarpine). Which of the following is the most important long-term complication to monitor for?

A. Coronary artery disease B. Renal failure C. B-cell Non-Hodgkin Lymphoma D. Pulmonary embolism E. Stroke

Answer: C. B-cell Non-Hodgkin Lymphoma

Explanation:

• Primary Sjögren's Syndrome carries a 44-fold increased risk of developing B-cell Non-Hodgkin Lymphoma, particularly MALT (mucosa-associated lymphoid tissue) lymphoma of the salivary glands
• Absolute lifetime risk is 5-10%
• Patients require annual surveillance (clinical examination for parotid/lymph node/spleen enlargement; monitoring C4, cryoglobulins, SPEP)
• Red flags: Persistent unilateral parotid swelling, declining C4, new cryoglobulinaemia, monoclonal spike on SPEP
• Coronary artery disease risk is slightly increased (chronic inflammation) but not the primary concern
• Renal failure is rare (RTA rarely progresses to ESRD; GN rare)
• Thrombotic risk is not significantly increased (unlike SLE)

3. Diagnostic Gold Standard Test

Question: A 50-year-old woman presents with a 2-year history of dry eyes (Schirmer test 3mm/5min bilaterally) and dry mouth. Her Anti-Ro and Anti-La antibodies are negative. Which investigation is the gold standard to confirm the diagnosis of Sjögren's Syndrome?

A. Parotid gland ultrasound B. Labial salivary gland biopsy C. MRI salivary glands D. Unstimulated whole salivary flow rate E. Repeat Anti-Ro in 6 months

Answer: B. Labial salivary gland biopsy

Explanation:

• Labial (minor) salivary gland biopsy is the gold standard for diagnosis
• Histopathology showing focal lymphocytic sialadenitis with a focus score ≥1 (≥1 focus of ≥50 mononuclear cells per 4mm² of glandular tissue) is diagnostic
• Scores 3 points in the 2016 ACR/EULAR classification criteria (highest single score)
• Essential for diagnosis in seronegative patients (Anti-Ro/La negative), who comprise ~30-40% of cases
• Parotid ultrasound, MRI, and salivary flow rate are supportive but not diagnostic on their own
• Repeating Anti-Ro in 6 months is unlikely to change if initially negative (seroconversion rare after symptom onset)

4. Treatment for Xerostomia

Question: A 48-year-old woman with primary Sjögren's Syndrome complains of severe dry mouth that interferes with eating and speaking. Saliva substitutes provide minimal relief. Which drug is most appropriate to stimulate salivary secretion?

A. Prednisolone B. Pilocarpine C. Hydroxychloroquine D. Methotrexate E. Ciclosporin

Answer: B. Pilocarpine

Explanation:

• Pilocarpine is a muscarinic M3 receptor agonist that stimulates exocrine gland secretion (saliva, tears, sweat)
• Dose: 5 mg three to four times daily
• Evidence: RCTs show modest improvement in xerostomia (NNT ~6); EULAR 2020 guidelines recommend pilocarpine for symptomatic xerostomia
• Side effects: Sweating (most common, 30-40%), flushing, nausea, urinary frequency, bradycardia
• Contraindications: Asthma (risk of bronchospasm), narrow-angle glaucoma, severe cardiac disease
• Prednisolone is ineffective for sicca symptoms (EULAR guidelines recommend against long-term corticosteroids)
• Hydroxychloroquine may help systemic symptoms (fatigue, arthralgia) but does not significantly improve sicca
• Methotrexate is for arthritis/vasculitis, not sicca
• Ciclosporin is used as eye drops for keratoconjunctivitis sicca, not oral xerostomia

5. Anti-Ro in Pregnancy

Question: A 32-year-old woman with primary Sjögren's Syndrome (Anti-Ro positive, Anti-La negative) is 8 weeks pregnant. She is concerned about risks to her baby. What is the most important risk associated with maternal Anti-Ro antibodies?

A. Neural tube defects B. Congenital complete heart block C. Cleft palate D. Renal agenesis E. Limb abnormalities

Answer: B. Congenital complete heart block

Explanation:

• Maternal Anti-Ro/SSA antibodies cross the placenta and can damage the fetal cardiac conduction system, causing congenital complete heart block (CHB)
• Risk: 1-2% in first pregnancy; 15-20% if previous child affected
• Mechanism: Anti-Ro antibodies bind to cardiac tissue (particularly L-type calcium channels and Ro52) → inflammation → fibrosis of AV node
• Timing: Damage occurs 16-24 weeks gestation (when maternal antibodies cross placenta and fetal AV node develops)
• Management:
  • Serial fetal echocardiography from 16-24 weeks (weekly during high-risk period)
  • Hydroxychloroquine throughout pregnancy (may reduce risk; continue if already on it)
  • "If incomplete heart block detected: Fluorinated corticosteroids (dexamethasone) may halt progression"
• Neonatal Lupus: Also caused by Anti-Ro; features include rash (annular erythema), cytopenias, hepatitis; transient (resolves as maternal antibodies clear by 6 months)
• CHB is permanent and usually requires pacemaker insertion in infancy

Viva Voce Scenarios

Scenario 1: Describe the Schirmer Test

Examiner: "How would you perform a Schirmer test to assess for dry eyes in Sjögren's Syndrome?"

Model Answer:

"The Schirmer test is a simple bedside test to assess tear production. There are two main types:

Schirmer I (Without Anaesthesia):

• This tests basal plus reflex tear secretion
• I would explain the procedure to the patient and obtain consent
• The patient sits comfortably with eyes closed
• I take a 5mm-wide sterile filter paper strip (Whatman No. 41 filter paper), folded at one end
• I place the folded end over the lower eyelid at the junction of the lateral and middle third of the conjunctival sac, avoiding the cornea
• The patient keeps their eyes gently closed (not squeezed shut) for 5 minutes
• After 5 minutes, I remove the strip and measure the length of wetting from the fold in millimetres

Interpretation:

• Normal: > 10 mm of wetting
• Abnormal (diagnostic of aqueous tear deficiency): ≤5 mm
• Borderline: 6-10 mm (may require repeat or alternative tests)

Schirmer II (With Anaesthesia and Nasal Stimulation):

• Topical anaesthetic (e.g., oxybuprocaine) applied to the eye first
• Nasal mucosa stimulated with cotton bud (to test reflex tearing)
• Less commonly used in routine practice

The Schirmer I test scores 1 point in the 2016 ACR/EULAR classification criteria if ≤5 mm in at least one eye."

Scenario 2: Investigating Suspected Lymphoma in Sjögren's

Examiner: "A 55-year-old woman with a 12-year history of primary Sjögren's Syndrome presents with progressive painless swelling of the left parotid gland over 6 months. What would be your approach?"

Model Answer:

"This is concerning for lymphoma transformation, specifically MALT (mucosa-associated lymphoid tissue) lymphoma of the parotid gland, given the persistent, progressive, painless, unilateral parotid swelling. Sjögren's Syndrome carries a 44-fold increased risk of B-cell Non-Hodgkin Lymphoma.

My Approach:

1. History:

• Duration, progression (gradual vs rapid), associated symptoms
• B symptoms: Fever, night sweats, weight loss
• Other lymph node swelling, splenomegaly symptoms (early satiety, LUQ pain)
• New skin lesions (purpura, vasculitis)
• Previous lymphoma risk factors: Cryoglobulinaemia, low C4, palpable purpura

2. Examination:

• Palpate parotid: Size, consistency (hard, firm, soft), fixation, tenderness
• Examine all lymph node regions (cervical, supraclavicular, axillary, inguinal)
• Abdominal examination: Hepatosplenomegaly
• Skin: Purpura, vasculitis

3. Investigations:

Blood Tests:

• FBC: Cytopenias (lymphoma infiltration or autoimmune)
• LDH: Raised in lymphoma (tumour burden marker)
• Serum Protein Electrophoresis (SPEP): Monoclonal spike (monoclonal gammopathy suggests clonal B-cell expansion)
• Complement C4: Low C4 is a risk factor for lymphoma
• Cryoglobulins: Positive in cryoglobulinaemic vasculitis; lymphoma association
• Rheumatoid Factor: Rising RF may indicate lymphoma transformation
• LFTs, U&Es: Baseline; hepatic/renal involvement

Imaging:

• Ultrasound parotid gland: Initial imaging (assess size, echotexture, vascularity); can guide biopsy
• CT or PET-CT neck, chest, abdomen, pelvis: Staging (if lymphoma confirmed); assess lymphadenopathy, splenomegaly, extranodal involvement

Biopsy:

• Parotid gland biopsy (ultrasound or CT-guided core biopsy, or surgical excisional biopsy)
  • "Histopathology: MALT lymphoma (marginal zone B-cell lymphoma), DLBCL, or other NHL"
  • "Immunohistochemistry: B-cell markers (CD20, CD79a), monoclonality (kappa/lambda light chain restriction)"
  • "Flow cytometry: Clonality assessment"
• Bone marrow biopsy: If systemic disease or cytopenias

4. MDT Discussion:

• Refer to haematology-oncology for management
• If MALT lymphoma confirmed: Staging (Ann Arbor); treatment (rituximab ± chemotherapy if localised; excellent prognosis if Stage I-II)
• If DLBCL: Aggressive chemotherapy (R-CHOP protocol)

Red Flags in this Case:

• Progressive, unilateral, painless parotid swelling = High suspicion for lymphoma
• Urgent biopsy required"

Scenario 3: Managing Extraglandular Manifestations

Examiner: "A 60-year-old woman with primary Sjögren's Syndrome presents with progressive dyspnoea and dry cough over 1 year. What is your differential diagnosis and management approach?"

Model Answer:

"Progressive dyspnoea and dry cough in a patient with Sjögren's Syndrome raises concern for pulmonary involvement, particularly interstitial lung disease (ILD), which occurs in 10-20% of primary Sjögren's patients.

Differential Diagnosis:

Sjögren's-Related Pulmonary Disease:

1. Interstitial Lung Disease (ILD): Most likely
   • NSIP (Non-Specific Interstitial Pneumonia): Most common pattern
   • LIP (Lymphocytic Interstitial Pneumonitis): Lymphocytic infiltration
   • UIP (Usual Interstitial Pneumonia): Rare
2. Small Airway Disease: Follicular bronchiolitis, bronchiectasis
3. Pulmonary Lymphoma: Rarely, MALT lymphoma or DLBCL

Other Causes (Less Likely but Consider):

• Infection (immunosuppressed patients)
• Drug-induced pneumonitis (methotrexate, if on DMARDs)
• Cardiac causes (heart failure)
• Other ILD (idiopathic pulmonary fibrosis, hypersensitivity pneumonitis)

Investigations:

1. Clinical Assessment:

• History: Duration, progression, exertional vs rest dyspnoea, orthopnoea, sputum, haemoptysis, weight loss, B symptoms
• Examination: Bibasal fine crackles (ILD), clubbing (rare in Sjögren's ILD), signs of cor pulmonale

2. Pulmonary Function Tests (PFTs):

• Restrictive defect: Reduced FEV1, FVC; FEV1/FVC ratio preserved or increased
• Reduced DLCO (diffusing capacity): Hallmark of ILD

3. High-Resolution CT Chest (HRCT):

• Gold standard for ILD diagnosis
• NSIP: Ground-glass opacities, reticular pattern, subpleural sparing
• LIP: Ground-glass, centrilobular nodules, thin-walled cysts
• UIP: Honeycombing, traction bronchiectasis, subpleural/basal predominance

4. Bronchoalveolar Lavage (BAL):

• Lymphocytosis (CD4+ predominance in Sjögren's ILD)
• Exclude infection (bacterial, fungal, PJP, TB)

5. Lung Biopsy (If Diagnosis Unclear):

• Video-assisted thoracoscopic surgery (VATS) biopsy
• Histopathology: NSIP, LIP, or other pattern
• Exclude lymphoma

6. Blood Tests:

• Inflammatory markers (ESR, CRP)
• Autoantibodies (Anti-Ro, ANA, RF)
• Exclude infection

7. Echocardiography:

• Assess for pulmonary hypertension (if dyspnoea disproportionate to ILD severity)

Management:

Mild, Stable ILD:

• Observation with serial PFTs and HRCT every 6-12 months
• Avoid smoking (including second-hand smoke)

Progressive or Symptomatic ILD:

1. Corticosteroids:

• Prednisolone 0.5-1 mg/kg/day (e.g., 30-60 mg daily)
• Taper over 3-6 months

2. Steroid-Sparing Immunosuppression:

• Mycophenolate Mofetil (MMF) 1-2 g/day in divided doses (first-line steroid-sparing agent)
• Rituximab: Increasing evidence for efficacy in Sjögren's-related ILD (1000 mg IV Day 0 and Day 14)
• Cyclophosphamide: For severe, progressive ILD (500-750 mg/m² IV monthly x 6 months)
• Azathioprine: Alternative steroid-sparing agent

3. Supportive Care:

• Oxygen therapy if hypoxic
• Pulmonary rehabilitation
• Treat infections promptly

4. MDT Approach:

• Rheumatology-Respiratory MDT: Joint management
• Consider lung transplant if end-stage ILD (rare)

Prognosis:

• NSIP: Better prognosis than UIP; often responsive to immunosuppression
• LIP: Usually responsive to treatment
• UIP: Poor prognosis; progressive fibrosis

In Summary:

• HRCT is key to diagnosis and pattern recognition
• Treat progressive/symptomatic ILD with immunosuppression
• Close monitoring with PFTs and HRCT"

---

14. References

Primary Sources

1. Baldini C, et al. Update on the pathophysiology and treatment of primary Sjögren syndrome. Nat Rev Rheumatol. 2024;20(8):473-491. doi:10.1038/s41584-024-01135-3. PMID: 38982205

2. Brito-Zerón P, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. doi:10.1038/nrdp.2016.47. PMID: 27383445

3. François H, et al. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol. 2016;12(2):82-93. doi:10.1038/nrneph.2015.174. PMID: 26568188

4. Tauqeer Z, et al. Ocular Pathophysiology of Sjögren's Syndrome. Ocul Immunol Inflamm. 2021;29(5):1046-1059. doi:10.1080/09273948.2021.1903935. PMID: 33830848

5. Belvoncikova P, et al. Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases. Int J Mol Sci. 2022;23(18):10729. doi:10.3390/ijms231810729. PMID: 36142642

6. André F, et al. Sjögren's syndrome. J Dtsch Dermatol Ges. 2022;20(8):1127-1141. doi:10.1111/ddg.14823. PMID: 35775593

7. Beydon M, et al. Epidemiology of Sjögren syndrome. Nat Rev Rheumatol. 2024;20(3):158-169. doi:10.1038/s41584-023-01057-6. PMID: 38110617

8. Brito-Zerón P, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. doi:10.1038/nrdp.2016.47. PMID: 27383445

9. Manfrè V, et al. Sjögren's syndrome: one year in review 2022. Clin Exp Rheumatol. 2022;40(12):2211-2224. doi:10.55563/clinexprheumatol/43z8gu. PMID: 36541236

10. Flament T, et al. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev. 2016;25(140):110-123. doi:10.1183/16000617.0011-2016. PMID: 27246587

11. Shiboski CH, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome. Arthritis Rheumatol. 2017;69(1):35-45. doi:10.1002/art.39859. PMID: 27785888

12. Jonsson R, et al. Current concepts on Sjögren's syndrome - classification criteria and biomarkers. Eur J Oral Sci. 2018;126 Suppl 1:37-48. doi:10.1111/eos.12536. PMID: 30178554

13. Negrini S, et al. Sjögren's syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9-25. doi:10.1007/s10238-021-00728-6. PMID: 34100160

14. Stefanski AL, et al. The Diagnosis and Treatment of Sjögren's Syndrome. Dtsch Arztebl Int. 2017;114(20):354-361. doi:10.3238/arztebl.2017.0354. PMID: 28610655

15. André F, et al. Sjögren's syndrome. J Dtsch Dermatol Ges. 2022;20(8):1127-1141. doi:10.1111/ddg.14823. PMID: 35775593

16. Ramos-Casals M, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi:10.1136/annrheumdis-2019-216114. PMID: 31672775

17. Vivino FB, et al. New Treatment Guidelines for Sjögren's Disease. Rheum Dis Clin North Am. 2016;42(3):531-551. doi:10.1016/j.rdc.2016.03.010. PMID: 27431353

18. Doolan G, et al. Treatment strategies for Sjögren's syndrome with childhood onset: a systematic review. Rheumatology (Oxford). 2022;61(4):1352-1364. doi:10.1093/rheumatology/keab579. PMID: 34289032

19. Kudsi M, et al. Severe Headache in Primary Sjögren's Syndrome Responded to Rituximab. Eur J Case Rep Intern Med. 2023;10(9):004051. doi:10.12890/2023_004051. PMID: 37789982

20. Ramos-Casals M, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010;304(4):452-460. doi:10.1001/jama.2010.1014. PMID: 20664046

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions must account for individual patient circumstances, local guidelines, and specialist input. Always consult appropriate specialists for diagnosis and management.